{"id":"axs-14-esreboxetine","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Increased blood pressure"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL2103809","moleculeType":"Small molecule","molecularWeight":"431.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By selectively inhibiting the norepinephrine transporter (NET), esreboxetine prevents the reuptake of norepinephrine from the synaptic cleft, leading to increased norepinephrine availability and enhanced noradrenergic neurotransmission. This mechanism is thought to improve mood, attention, and pain perception, making it potentially useful in depression and other neuropsychiatric conditions.","oneSentence":"Esreboxetine is a norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the central nervous system by blocking its reuptake at the presynaptic neuron.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:09.872Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Major depressive disorder"},{"name":"Treatment-resistant depression"}]},"trialDetails":[{"nctId":"NCT07398417","phase":"PHASE3","title":"Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design","status":"RECRUITING","sponsor":"Axsome Therapeutics, Inc.","startDate":"2026-01-14","conditions":"Fibromyalgia","enrollment":620}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AXS-14 (Esreboxetine)","genericName":"AXS-14 (Esreboxetine)","companyName":"Axsome Therapeutics, Inc.","companyId":"axsome-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Esreboxetine is a norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the central nervous system by blocking its reuptake at the presynaptic neuron. Used for Major depressive disorder, Treatment-resistant depression.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}